Cytokinetics, Incorporated
(NASDAQ : CYTK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.48%197.801.2%$611.09m
GILDGilead Sciences, Inc.
0.34%68.240.9%$504.92m
CELGCelgene Corporation
-2.83%67.441.2%$479.41m
BIIBBiogen Inc.
0.71%321.461.3%$470.90m
ILMNIllumina, Inc.
0.46%302.973.5%$383.45m
REGNRegeneron Pharmaceuticals, Inc.
-0.28%338.052.6%$297.84m
VRTXVertex Pharmaceuticals Incorporated
-0.81%159.771.9%$258.44m
ALXNAlexion Pharmaceuticals, Inc.
1.73%117.052.0%$202.52m
AAgilent Technologies, Inc.
7.25%67.151.5%$199.47m
SRPTSarepta Therapeutics, Inc.
1.81%118.4715.4%$149.43m
LGNDLigand Pharmaceuticals Incorporated
1.68%151.0423.3%$141.92m
EXASExact Sciences Corporation
-2.30%65.7325.3%$133.86m
TSROTESARO, Inc.
14.04%42.0014.4%$124.75m
NKTRNektar Therapeutics
0.13%38.065.6%$122.40m
INCYIncyte Corporation
-0.62%63.852.5%$115.02m

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.